Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP Therapy) in patients with advanced pancreatic cancer

Japanese Journal of Clinical Oncology

Volumn 26, Issue 4, 1996, Pages 215-220

  Okusaka, Takuji ^a   Okada, Shuichi ^a   Ishii, Hiroshi ^a   Nose, Haruhiko ^a   Nakasuka, Hidekazu ^a   Nakayama, Hidetsugu ^a   Nagahama, Hiroyasu ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Clinical response; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MORTALITY; PAIN; PANCREAS TUMOR; PATHOPHYSIOLOGY; REMISSION; SURVIVAL RATE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PAIN; PANCREATIC NEOPLASMS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0030210863     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jjco.a023217     Document Type: Article

References (14)

1. Brennan MF, Kinsella T, Friedman M: Cancer of the pancreas. In Cancer: Principles and Practice of Oncology, 3rd ed, Debita VT, Hellman S, Rosenberg SA, eds, Lippincott, Philadelphia. p800-835, 1989
2. Lebovits AH, Lefkowitz M: Pain management of pancreatic carcinoma: a review. Pain 36: 1-11, 1989
3. Schipper H, Clinch J, McMurray A, Levitt M: Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 2: 472-483, 1984
4. Hansen R, Quebbeman E, Ritch P, Chitambar C, Anderson T: Continuous 5-Fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci 295: 91-93, 1988
5. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34, 1994
6. Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC, Foley KM: The Memorail Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 60: 1151-1158, 1987
7. Andersen JS, Burris HA, Casper E, Clayman M, Green M, Nelson RL, Portenoy R, Rothenberg M, Tarassoff PG, Von Hoff DD: Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 13: 461, 1994 (abstract)
8. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment: offset publication 48, World Health Organization, Genova. 1979
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 63: 457-481, 1958
10. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966
11. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trial requiring prolonged observation of each patient: I, introduction and design Br J Cancer 34: 585-612, 1976
12. Aoki K, Okada S, Moriyama N, Ishii H, Nose H, Yoshimori M, Kosuge T, Ozaki H, Wakao F, Takayasu K, Mukai K: Accuracy of computed tomography in determining pancreatic cancer tumor size. Jpn J Clin Oncol 24: 85-87, 1994
13. Rothenberg ML, Burns HA III, Andersen JS, Moore M, Green MR, Portenoy RK, Casper ES, Tarassoff PG, Storniolo AM, Von Hoff DD: Gemcitabine: effective palliative therapy for pancreas cancer patients failing 5-FU. Proc Am Soc Clin Oncol 14: 198, 1995 (abstract)
14. Moore M, Andersen J, Burns H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R, Storniolo A, Von Hoff D: A randomized trial of gemcitabine versus 5-FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 14: 199, 1995 (abstract)